Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Axogen, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Axogen, Inc. (“Axogen” or “the Company”) (NASDAQ: AXGN). Investors who purchased Axogen securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Axogen has violated federal securities laws.
Investigation Details
On August 25, 2025, Axogen issued a press release “announcing that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance® Nerve Graft by three months to December 5, 2025.” Following this news, Axogen stock dropped more than 9% on the same day.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Axogen securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
AXGN — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”